Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A
Marcin Kowanetz, Christina Rabe, Yuanyuan Xiao, Qun J Wu, Hartmut Koeppen, Cecilia Leddy, Rajesh D Patel, John Powderly, Holbrook Kohrt, Scott Gettinger, Jean-Charles Soria, Roy S Herbst, Rupal Desai, Mitchell Denker, Jane Ruppel, Marigold Boe, Rin Nakamura, Ling Fu, Teiko Sumiyoshi, Ahmad Mokatrin, Xiaodong Shen, Gregg Fine, Daniel S Chen, Priti S Hegde
Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P136; DOI: 10.1186/2051-1426-2-S3-P136
